SCHEMBL20148056

SCHEMBL20148056

CC1(NC(=O)c2ccccc2C(F)(F)F)CCN(C(C)(C)C)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
GAA P10253 1/20 0.48
RET P07949 1/20 0.43
TP53 P04637 1/20 0.41
RECQL P46063 1/20 0.41
SLC6A9 P48067 3/20 0.41
SCD O00767 1/20 0.40
PTGS1 P23219 1/20 0.39
KCNK3 O14649 1/20 0.39
KCNK9 Q9NPC2 1/20 0.39
CCR3 P51677 1/20 0.39
DPP4 P27487 1/20 0.39
DPP7 Q9UHL4 1/20 0.39
CXCR5 P32302 1/20 0.39
P2RX7 Q99572 1/20 0.39
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
OPRM1 P35372 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20069770 0.87 LMNA (0.50) LMNAGAARETTP53RECQL
SCHEMBL20147980 0.85 GAA (0.45) LMNAGAARETTP53CCR3
SCHEMBL25503721 0.84 LMNA (0.47) LMNAGAARETTP53RECQL
SCHEMBL20147566 0.84 LMNA (0.47) LMNAGAARETTP53RECQL
SCHEMBL20147987 0.80 FAAH (0.50) RETTP53P2RX7
SCHEMBL22857088 0.78 GAA (0.43) LMNAGAARETTP53SLC6A9
SCHEMBL20148036 0.77 RET (0.43) RETCCR3GRIN2DGRIN3BCHRM2
SCHEMBL20626718 0.73 KDM4E (0.45) LMNAGAARETKCNH2
SCHEMBL4716887 0.73 SCD (0.56) SCD
SCHEMBL20147547 0.73 RET (0.43) RETSLC6A9CCR3DPP4P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-10-15 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 LMNA 1968/4885GAA 3183/4885RET 1/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 LMNA 1968/4885GAA 3183/4885RET 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.